Meet James | Pradaxa® Patient Profiles | Boehringer Ingelheim

Meet James

  • 66 years old
  • Enjoys swimming and travelling
    around the world with his wife
  • Recently diagnosed with nonvalvular atrial fibrillation
    (NVAF) but is not yet on treatment

What will you and James
discuss when considering
treatment options?

What are the risks of
major bleeding?
What happens if he is
ever injured?
Scroll to
find out

With Pradaxa®, James can feel confident
staying active

Major bleeding risk among NOACs vs warfarin (n=61,678), as measured
in an independent, real-world, observational analysis1
‘Novel Oral Anticoagulants have less major bleeding risk vs Warfarin’

Not a head-to-head study; this was a real-world, observational analysis comparing the effectiveness and safety of standard doses of Pradaxa®, rivaroxaban, and apixaban vs warfarin.

Life Happens

If James ever needs it, Praxbind® provides the reassurance of specific, immediate, and complete reversal of Pradaxa®

  • Dual indication—for life-threatening or uncontrolled bleeding and emergency surgery/urgent procedures2

  • Specific binding allows for immediate and complete reversal of Pradaxa® with no procoagulant effects2

  • Easy to use—1 ready-to-use dose for ALL Pradaxa® patients2

  • Widely available—8,300+ sites in 48 countries3

  • References:
  • 1. Larsen TB et al. BMJ. 2016;353:i3189.
  • 2. Praxbind® (idarucizumab) Summary of Product Characteristics. 2018. 
  • 3. Data on file, Boehringer Ingelheim.